Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5972968 A
Publication typeGrant
Application numberUS 08/899,288
Publication dateOct 26, 1999
Filing dateJul 23, 1997
Priority dateJul 26, 1996
Fee statusLapsed
Also published asCA2211444A1, CA2211444C, CN1090620C, CN1174192A, DE69703915D1, DE69703915T2, EP0820990A2, EP0820990A3, EP0820990B1
Publication number08899288, 899288, US 5972968 A, US 5972968A, US-A-5972968, US5972968 A, US5972968A
InventorsGuillaume de Nanteuil, Bernard Portevin, Jacqueline Bonnet, Armel Fradin
Original AssigneeAdir Et Compagnie
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Benzimidazole, benzoxazole and benzothiazole compounds
US 5972968 A
Abstract
A compound of formula (I): ##STR1## in which: R1 represents halogen or hydroxyl, alkoxy, trihalomethyl, amino, mercapto, alkylthio, trialkylammonium, aryloxy, arylthio, arylsulfonyl, arylsulfonyloxy, cycloalkyloxy, cycloalkylthio, bicycloalkyloxy or bicycloalkylthio,
Ra and Rb, which may be identical or different, represent hydrogen or alkyl,
X represents oxygen or sulfur or NR,
Y represents the group as defined in the description,
R2 represents an optionallly substituted aryl,
its optical isomers as well as its addition salts with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as interleukin-1β inhibitor.
Images(11)
Previous page
Next page
Claims(14)
We claim:
1. A compound selected from those of formula (I): ##STR14## in which: R1 represents halogen, hydroxyl, linear or branched (C1 -C6) alkoxy optionally substituted with an aryl group, trihalomethyl, amino optionally substituted with one or more linear or branched (C1 -C6) alkyl groups or optionally substituted aryl groups, mercapto, linear or branched (C1 -C6) alkylthio, linear or branched (C1 -C6) trialkylammonium, aryloxy, arylthio, arylsulfonyl, arylsulfonyloxy, (C3 -C7) cycloalkyloxy or (C3 -C7) cycloalkylthio, (C6 -C8) bicycloalkyloxy optionally substituted with aryl or (C6 -C8) bicycloalkylthio optionally substituted with aryl, wherein each aryl means pyridyl or phenyl,
Ra and Rb, which may be identical or different, represent hydrogen or linear or branched (C1 -C6) alkyl,
X represents a group NR in which R represents a hydrogen atom or a linear or branched (C1 -C6) alkyl group,
Y represents --(CH2)m --Z--(CH2)n -- wherein:
m is 0, 1 or 2,
n is 0, 1 or 2,
Z represents sulfur linear or branched (C1 -C6) alkyl substituted with a linear or branched (C1 -C6) alkyl or --SO2 --, --CHOH--, or --CH(CH2 OH)--, a pyridine ring being present in at least one of R1 and R2,
R2 represents optionally substituted pyridyl or phenyl,
or an optical isomer or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein Y represents a sulfur atom.
3. A compound of claim 1, wherein R1 represents hydroxyl.
4. A compound of claim 1, wherein R1 represents mercapto.
5. A compound of claim 1, wherein R1 represents optionally substituted arylthio or aryloxy wherein aryl is pyridyl or phenyl.
6. A compound of claim 5, wherein R1 represents optionally substituted phenoxy or phenylthio.
7. A compound of claim 1, wherein R2 represents optionally substituted phenyl.
8. A compound of claim 1, wherein R2 represents optionally substituted pyridyl.
9. The compound of claim 1, which is 2-phenoxymethyl 5-(4-pyridylthio)benzimidazole.
10. The compound claim 1, which is 2-phenoxymethyl-5-(N-methyl-4-pyridylamino)benzimidazole.
11. A pharmaceutical composition useful as an interleukin-1β inhibitor comprising as active principle an effective amount of a compound as claimed in claim 1, together with one or more pharmaceutically-acceptable excipients or vehicles.
12. A pharmaceutical composition useful as an interleukin-1β inhibitor comprising as active principle an effective amount of the compound of claim 10, together with one or more pharmaceutically-acceptable excipients or vehicles.
13. A method for treating a living body afflicted with a condition requiring an interleukin-1β inhibitor comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said condition.
14. A method for treating a living body afflicted with a condition requiring an interleukin-1β inhibitor comprising the step of administering to the living body an amount of a compound of claim 10 which is effective for alleviation of said condition.
Description
BACKGROUND OF THE INVENTION

These compositions, besides being new, are potent interleukin-1β (IL-1β) inhibitors.

DETAILED DESCRIPTION OF THE INVENTION

IL-1β is produced by macrophages, and possesses a wide variety of biological activities associated with inflammatory pathologies such as rheumatoid arthritis or osteoarthritis. IL-1β stimulates the cells present in the joint which synthesize and thus express inducible cyclooxygenase (COX2), as well as inducible NO synthase, to yield prostaglandins and NO which are important mediators of pain and inflammation. IL-1β also activates the expression and the synthesis of proteases which participate in the degradation of the extracellular matrix of the chondrocytes and in the abolition of the synthesis of the components of the cartilage matrix. Furthermore, IL-1β is involved in the activation of endothelial cells, which then express various adhesion factors, as well as in the induction of other proinflammatory cytokines such as TNF or chemokines (IL-6). Lastly, IL-1β plays a part in the regulation of bone resorption, as well as in differentiation and lymphocyte proliferation.

An IL-1β inhibitor can hence be expected to act against the inflammatory phenomena and to modify in a favorable manner the course of pathologies such as rheumatoid arthritis or osteoarthritis.

More specifically, the present invention relates to the compounds of formula (I): ##STR2## in which: R1 represents a halogen atom, a hydroxyl, linear or branched (C1 -C6) alkoxy (optionally substituted with an aryl group), trihalomethyl, amino (optionally substituted with one or more linear or branched (C1 -C6) alkyl groups or optionally substituted aryl groups), mercapto, linear or branched (C1 -C6) alkylthio, linear or branched (C1 -C6) trialkylammonium, aryloxy, arylthio, arylsulfonyl, arylsulfonyloxy, (C3 -C7) cycloalkyloxy or (C3 -C7) cycloalkylthio group, a (C6 -C8) bicycloalkyloxy group optionally substituted with an aryl group or a (C6 -C8) bicycloalkylthio group optionally substituted with an aryl group,

Ra and Rb, which may be identical or different, represent a hydrogen atom or a linear or branched (C1 -C6) alkyl group,

X represents an oxygen or sulfur atom or a group NR (in which R represents a hydrogen atom or a linear or branched (C1 -C6) alkyl group),

Y represents --(CH2)m --Z--(CH2)n -- wherein:

m is 0, 1 or 2,

n is 0, 1 or 2,

Z represents an oxygen or sulfur atom or an amino group (optionally substituted with a linear or branched (C1 -C6) alkyl group) or an --SO2 --, --CHOH--, --CH2 -- or --CH(CH2 OH)-- group,

R2 represents an optionally substituted aryl group,

their isomers as well as their addition salts with a pharmaceutically acceptable acid or base.

Among pharmaceutically acceptable acids, there may be mentioned, without implied limitation, hydrochloric, hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, oxalic, methanesulfonic, camphoric, and the like, acids.

Among pharmaceutically acceptable bases, there may be mentioned, without implied limitation, sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine, and the like.

Optionally substituted aryl group is understood to mean a mono- or bicyclic aromatic group optionally containing a nitrogen atom, optionally substituted with one or more halogen atoms or linear or branched (C1 -C6) alkyl, linear or branched (C1 -C6) trihaloalkyl, linear or branched (C1 -C6) alkoxy, hydroxyl, nitro, cyano, amino (optionally substituted with one or more linear or branched (C1 -C6) alkyl groups), substituted phenyl or substituted bicycloalkyl groups.

Among preferred aryl groups, the following groups, substituted or otherwise, may be mentioned: phenyl, naphthyl, pyridyl, quinolyl, imidazolyl or pyridyl N-oxide.

Preferred compounds of the invention are the compounds of formula (I) in which X represents a group --NR (in which R represents a hydrogen atom or a linear or branched (C1 -C6) alkyl group).

Preferred groups R2 according to the invention are phenyl and pyridyl groups, each of these groups being optionally substituted.

Preferred groups R1 according to the invention are hydroxyl, mercapto, aryloxy and arylthio groups.

Preferred compounds according to the invention are the compounds of formula (I) in which Y represents an oxygen or sulfur atom or an eventually substituted amino group,

The present invention also extends to the process for preparing the compounds of formula (I). When the compounds of formula (I) which it is desired to obtain are such that X=NR, the process is distinguished by the fact that a compound of formula (II):

R2 --Y--H                                             (II)

in which R2 and Y are as defined in the formula (I), is used as starting material, which is reacted with 2-nitro-5-chloroaniline,

to yield the compound of formula (III): ##STR3## in which R2 and Y are as defmed in the formula (I), which undergoes a catalytic reduction, to yield the compound of formula (IV): ##STR4## in which R2 and Y are as defined in the formula (I), which is reacted in an acid medium with a compound of formula (V): ##STR5## in which Ra, Rb and R1 have the same meaning as in the formula (I),

to yield the compound of formula (I/a), a special case of the compounds of formula (I): ##STR6## in which R1, Ra, Rb, R2 and Y are as defined in the formula (I),

which undergoes, where appropriate, when R1 represents a hydroxyl group, the action of thionyl chloride,

to yield the compound of formula (I/b), a special case of the compounds of formula (I): ##STR7## in which R2, Y, Ra and Rb have the same meaning as in the formula (I),

which can then undergo the standard reactions which can be carried out on chlorinated compounds, to obtain the corresponding substitutions;

which compound of formula (I/a) or (I/b):

can, where appropriate, undergo substitution of its NH function with a linear or branched (C1 -C6) alkyl group,

can be purified, if need be, according to a conventional purification technique,

is separated, if need be, into its isomers according to a conventional separation technique,

is converted, if so desired, to its addition salts with a pharmaceutically acceptable base.

The compounds of formula (III) described above can also be obtained by reacting a halogenated compound of formula R2 --Y-hal (such that R2 and Y are as defined in the formula (I) and hal represents a halogen atom) with a hydroxynitroaniline.

When the compounds of formula (I) which it is desired to obtain are such that X=X'=O or S, the process is distinguished by the fact that a compound of formula (VI): ##STR8## in which R2 and Y are as defined in the formula (I) and X' represents an oxygen or sulfur atom, is used as starting material, which is reacted with nitric acid,

to yield the compound of formula (VI): ##STR9## in which R2, Y and X' are as defined above, which undergoes a catalytic hydrogenation, to yield the compound of formula (VIII): ##STR10## which is reacted in an acid medium with a compound of formula (V): ##STR11## in which Ra, Rb and R1 have the same meaning as in the formula (I),

to yield the compound of formula (I/c), a special case of the compounds of formula (I): ##STR12## in which R2, Y, X', Ra, Rb and R1 are as defined above,

which undergoes, where appropriate, when R1 represents a hydroxyl group, the action of thionyl chloride,

to yield the compound of formula (I/d), a special case of the compounds of formula (I): ##STR13## in which R2, X', Y, Ra and Rb have the same meaning as above,

which can then undergo the standard reactions which can be carried out on chlorinated compounds, to obtain the corresponding substitutions;

which compound of formula (I/c) or (I/d):

can be purified, if need be, according to a conventional purification technique,

is separated, if need be, into its isomers according to a conventional separation technique,

is converted, if so desired, to its addition salts with a pharmaceutically acceptable base.

The invention also extends to pharmaceutical compositions containing as active principle at least one compound of formula (I) with one or more suitable nontoxic, inert excipients. Among the pharmaceutical compositions according to the invention, there may be mentioned more especially those which are suitable for oral, parenteral (intravenous or subcutaneous), or nasal administration, simple or sugar-coated tablets, sublingual tablets, hard gelatin capsules, troches, suppositories, creams, ointments, skin gels, injectable preparations, suspensions to be swallowed, and the like.

The appropriate dosage can be adapted to suit the nature and severity of the complaint, the administration route and also the patient's age and weight. This dosage varies from 0.1 to 100 mg daily in one or more doses.

The examples which follow illustrate the invention but in no way limit it.

The starting materials used are known products or are prepared according to known procedures.

The structures of the compounds described in the examples and the preparations were determined according to standard spectrophotometric techniques (infrared, NMR, mass spectrometry, etc.).

EXAMPLE 1 2-Hydroxymethyl-5-(4-pyridyloxy)benzimidazole

Stage 1: 2-Amino-4-(4-pyridyloxy)nitrobenzene

A 2-liter round-bottomed flask is charged with 35.2 g (0.369 mol) of 4-hydroxypyridine and 250 ml of anhydrous dimethylformamide (DMF). Under nitrogen, 42 g (0.369 mol) of potassium tert-butylate are added portionwise while the temperature is maintained at 15-20 C. with a water/ice bath. After the addition, the mixture is stirred for 2 hours and a pale yellow solution is obtained. 60 g (0.358 mol) of 2-nitro-5-chloroaniline are then added and an intense red coloration is obtained. The mixture is brought to 100 C. for 6 hours and then allowed to cool overnight. The DMF is evaporated off and water is then added; a precipitate is obtained, which is filtered off and washed with isopropanol in the heated state and then dried.

Melting point: >260 C.

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     57.14         3.92   18.17found     56.93         3.98   17.75______________________________________

Stage 2: 2-Amino-4-(4-pyridyloxy)aniline

30 g (0.130 mol) of 2-amino-4-(4-pyridyloxy)nitrobenzene obtained in the preceding stage are suspended in 600 ml of a water/citric acid (50:50) mixture. 2 g of 10% palladium on charcoal are added and the mixture is hydrogenated for 18 h at 4 kg pressure and at room temperature. The catalyst is filtered off and the filtrate is evaporated. The residue is dissolved in water. This aqueous phase is alkalinized with potassium carbonate. The precipitate obtained is filtered off, washed with water and dried. The expected product is purified by chromatography on silica gel (eluent: CH2 Cl2 /MeOH, 80:20).

Melting point: 260 C.

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     65.66         5.51   20.88found     65.78         5.54   20.79______________________________________

Stage 3: 2-Hydroxymethyl-5-(4-pyridyloxy)benzimidazole

A 250-ml round-bottomed flask equipped with a stirrer and a condenser is charged with 3 g (14.9 mmol) of the compound obtained in the preceding stage, 30 ml of 4N hydrochloric acid and 2.1 g (50% excess) of glycolic acid. The mixture is brought to reflux for 6 hours and then allowed to cool. On alkalinization with 10N sodium hydroxide, the product precipitates and is filtered off, washed with 3 times 30 ml of water and dried in a desiccator. The product is purified by chromatography on silica gel (eluent: CHCl2 /MeOH/NH2 OH, 80:20:1).

Melting point: 250 C.

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     64.72         4.60   17.42found     64.60         5.04   17.35______________________________________
EXAMPLE 2 2-Chloromethyl-5-(4-pyridyloxy)benzimidazole dihydrochloride

A 250-ml round-bottomed flask equipped with a stirrer and a condenser is charged with 3.18 g (13.2 mmol) of 2-hydroxymethyl-5-(4-pyridyloxy)benzimidazole obtained in Example 1 and 40 ml of thionyl chloride. The mixture is brought to reflux for 2 hours and then cooled. The precipitate is filtered off, washed with ether and dried, and yields the expected product.

Melting point: >250 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % Cl-  %______________________________________calculated    46.94     3.64   12.63   31.98                                  21.32found    46.13     3.62   12.09   32.04                                  21.06______________________________________
EXAMPLE 3 2-Hydroxymethyl-5-phenoxybenzimidazole

Stage 1: 2-Amino-4-phenoxynitrobenzene

The expected product is obtained according to the process described in Stage 1 of Example 1, replacing 4-hydroxypyridine by phenol.

Melting point: 150 C.

Stage 2: 2-Amino-4-phenoxyaniline

23.6 g (0.109 mol) of 2-amino-4-phenoxynitrobenzene obtained in the preceding stage are dissolved in 550 ml of dioxane. After hydrogenation (H2 /Pd) for 18 h at room temperature and at 4 kg pressure, the catalyst is filtered off and the filtrate is evaporated. The residue is taken up with pentane, filtered and dried, and yields the expected product.

Melting point: 72 C.

Stage 3: 2-Hydroxymethyl-5-phenoxybenzimidazole

19.4 g (97 mmol) of the compound obtained in the preceding stage, 155 ml of 4N HCl and 14.2 g (50% excess) of glycolic acid are brought to reflux for 5 hours with stirring. The mixture is allowed to cool. The hydrochloride of the expected product precipitates, and is filtered off, rinsed with water and dried.

Melting point: 220 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % Cl-  %______________________________________calculated    60.77     4.73   10.12   12.81                                  12.81found    60.67     4.76   10.07   12.81                                  12.98______________________________________

On alkalinization of the hydrochloride with 10N sodium hydroxide, and after filtration, washing with water and drying, the expected product is recovered in free base form.

Melting point: 200 C.

EXAMPLE 4 2-Chloromethyl-5-phenoxybenzimidazole hydrochloride

3.6 g (15 mmol) of the compound described in Example 3, 60 ml of toluene and 8 ml of thionyl chloride are brought to reflux for 1 h 30 min. After filtration and drying, the expected product is obtained.

Melting point: 172 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % Cl-  %______________________________________calculated    56.97     4.10   9.49    24.02                                  12.01found    56.06     4.08   9.30    23.86                                  11.92______________________________________
EXAMPLE 5 (5-Phenoxy-2-benzimidazolyl)methyltrimethylammonium chloride

2 g (6.8 mmol) of the compound described in Example 4 are suspended in 100 ml of acetone. 6.6 g of a 33% solution of trimethylamine in ethanol are added. The medium solubilizes instantaneously. After stiring overnight at room temperature, the mixture is evaporated. The residue is purified on a Biogel column (CH3 CN/H2 O, 50:50) and then crystallized in acetone. The expected product is obtained after filtration and drying.

Melting point: 238-240 C.

______________________________________Elemental microanalysis:     C %  H %        N %    Cl-  %______________________________________calculated  64.25  6.34       13.22                              11.16found       64.19  6.49       12.86                              11.02______________________________________

The examples which follow were obtained according to the process described in Example 3, from the corresponding starting materials.

EXAMPLE 6 2-Mercaptomethyl-5-phenoxybenzimidazole

From mercaptoethanoic acid.

Melting point: 168 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    57.43     4.48   9.57    12.11                                  10.95found    57.27     4.53   9.27    12.40                                  10.49______________________________________
EXAMPLE 7 2-Aminomethyl-5-phenoxybenzimidazole

From glycine.

Melting point: 123 C.

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     70.28         5.48   17.56found     69.96         5.67   17.26______________________________________
EXAMPLE 8 2-(Trifluoromethyl)methyl-5-phenoxybenzimidazole

From trifluoromethylethanoic acid.

Melting point: 188 C.

EXAMPLE 9 2-Methoxymethyl-5-phenoxybenzimidazole

From methoxyethanoic acid.

Melting point: 74 C.

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     70.85         5.55   11.02found     70.93         5.85   10.89______________________________________
EXAMPLE 10 2-Tosyloxymethyl-5-phenoxybenzimidazole

By reacting the compound described in Example 3 with tosyl chloride.

Melting point: 138 C.

______________________________________Elemental microanalysis:     C %  H %        N %    S %______________________________________calculated  63.95  4.60       7.10 8.13found       64.02  4.67       7.09 7.98______________________________________
EXAMPLE 11 2-(2-Hydroxy-2-propyl)-5-phenoxybenzimidazole

Melting point: 186 C.

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     71.62         6.01   10.44found     71.96         6.11   10.28______________________________________
EXAMPLE 12 2-Hydroxymethyl-5-(4-aminophenoxy)benzimidazole dihydrochloride

Melting point: >250 C.

______________________________________Elemental microanalysis:     C %  H %        N %    Cl %______________________________________calculated  51.24  4.61       12.80                              21.60found       51.02  4.99       12.26                              21.01______________________________________
EXAMPLE 13 5-(1-Phenyl-1-aminomethyl)-2-(hydroxymethyl)benzimidazole dihydrochloride

Melting point: 200 C.

______________________________________Elemental microanalysis:     C %  H %        N %    Cl %______________________________________calculated  55.23  5.25       12.88                              21.74found       55.82  5.39       12.74                              22.58______________________________________
EXAMPLE 14 5-(1-Phenyl-1-hydroxymethyl)-2-(hydroxymethyl)benzimidazole hydrochloride

Melting point: >260 C.

______________________________________Elemental microanalysis:     C %  H %        N %    Cl %______________________________________calculated  61.97  5.20       9.63 12.19found       62.04  5.27       9.52 12.66______________________________________
EXAMPLE 15 2-Hydroxymethyl-5-(4-pyridylthio)benzimidazole dihydrochloride

Melting point: >260 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    47.28     3.97   12.72   21.47                                  9.71found    47.16     3.92   12.24   21.65                                  9.93______________________________________
EXAMPLE 16 2-Hydroxymethyl-5-(3-pyridyloxy)benzimidazole dihydrochioride

Melting point: 185 C.

______________________________________Elemental microanalysis:     C %  H %        N %    Cl %______________________________________calculated  49.70  4.17       13.37                              22.57found       49.30  4.97       13.05                              22.59______________________________________
EXAMPLE 17 2-Hydroxymethyl-5-(2-pyridylthio)benzimidazole dihydrochloride

Melting point: 190 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    47.28     3.97   12.72   21.47                                  9.71found    46.95     4.05   12.63   21.67                                  9.96______________________________________
EXAMPLE 18 2-Phenoxymethyl-5-(4-pyridylthio)benzimidazole dihydrochloride

Melting point: 160 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    56.16     4.22   10.34   17.45                                  7.89found    57.27     4.09   10.31   17.58                                  7.89______________________________________
EXAMPLE 19 2-Hydroxymethyl-5-[(7-trifluoromethyl-4-quinolyl)thio]benzimidazole

Melting point: 242 C.

______________________________________Elemental microanalysis:     C %  H %        N %    S %______________________________________calculated  57.60  3.22       11.19                              8.54found       57.68  3.54       10.80                              8.21______________________________________
EXAMPLE 20 2-Hydroxymethyl-5-[(2-imidazolyl)thio]benzimidazole dihydrochloride

Melting point: >260 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    41.39     3.79   17.55   22.21                                  10.04found    41.36     3.88   17.08   22.45                                  10.05______________________________________
EXAMPLE 21 2-(4-Pyridylthiomethyl)-5-(4-pyridylthio)benzimidazole trihydrochloride

Melting point: >260 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    47.01     3.73   12.19   23.13                                  13.93found    47.31     4.01   12.16   23.27                                  14.10______________________________________
EXAMPLE 22 2-Phenylthiomethyl-5-(4-pyridylthio)benzimidazole dihydrochloride

Melting point: 168 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    54.03     4.06   9.95    16.79                                  15.18found    53.61     4.24   9.71    17.28                                  14.82______________________________________
EXAMPLE 23 2-Hydroxymethyl-5-(3-pyridylthio)benzimidazole dihydrochloride

Melting point: 260 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    47.28     3.97   12.72   21.47                                  9.71found    46.41     3.86   12.34   22.57                                  9.58______________________________________
EXAMPLE 24 2-(4-Chlorophenoxymethyl)-5-(4-pyridylthio)benzimidazole dihydrochloride

Melting point: 198 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    51.77     3.66   9.53    24.13                                  7.27found    52.43     3.71   9.60    24.24                                  6.93______________________________________
EXAMPLE 25 2-(Phenylsulfonylmethyl)-5-(4-pyridylthio)benzimidazole dihydrochloride

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    50.22     3.77   9.25    15.60                                  14.11found    50.54     3.97   9.22    16.09                                  14.17______________________________________
EXAMPLE 26 2-Phenoxymethyl-5-(4-pyridylsulfonyl N-oxide)benzimidazole

Melting point: 210 C.

______________________________________Elemental microanalysis:     C %  H %         N %    S %______________________________________calculated  59.83  3.96        11.02                               8.41found       59.68  3.99        11.04                               8.13______________________________________
EXAMPLE 27 2-Phenoxymethyl-5-(4-pyridylsulfonyl)benzimidazole dihydrochloride

Melting point: 174 C.

______________________________________Elemental microanalysis:  C %     H %    N %       Cl % S %______________________________________calculated    52.06     3.92   9.59    16.18                                  7.31found    52.27     4.01   9.30    15.44                                  6.64______________________________________
EXAMPLE 28 2-Benzyloxymethyl-5-(4-pyridylthio)benzimidazole

______________________________________Elemental microanalysis:     C %  H %         N %    S %______________________________________calculated  69.14  4.93        12.09                               9.23found       69.43  4.92        12.08                               9.62______________________________________
EXAMPLE 29 2-(2-Naphthyloxymethyl)-5-(4-pyridylthio)benzimidazole

______________________________________Elemental microanalysis:     C %  H %         N %    S %______________________________________calculated  72.04  4.47        10.96                               8.30found       72.26  4.41        11.00                               8.30______________________________________
EXAMPLE 30 2-(1-Naphthyloxymethyl)-5-(4-pyridylthio)benzimidazole

______________________________________Elemental microanalysis:     C %  H %         N %    S %______________________________________calculated  72.04  4.47        10.96                               8.36found       72.46  4.41        10.80                               8.57______________________________________
EXAMPLE 31 2-Phenoxymethyl-5-(N-methyl-4-pyridylamino)benzimidazole dihydrochloride

______________________________________Elemental microanalysis:     C %  H %         N %    Cl %______________________________________calculated  59.56  5.00        13.89                               17.58found       59.32  5.01        13.79                               18.61______________________________________
EXAMPLE 32 2-Phenoxymethyl-5-(3-pyridylthio)benzimidazole

Melting point: 118 C.

______________________________________Elemental microanalysis:     C %  H %         N %    S %______________________________________calculated  68.45  4.53        12.60                               9.62found       68.77  4.60        12.68                               9.82______________________________________
EXAMPLE 33 2-Phenoxymethyl-5-[(RS)-α-hydroxybenzyl]benzimidazole

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     76.34         5.49   8.48found     76.04         5.54   8.29______________________________________
EXAMPLE 34 2-Hydroxymethyl-5-(4-pyridylamino)benzimidazole dihydrochloride

Melting point: >250 C.

______________________________________Elemental microanalysis:     C %  H %         N %    Cl %______________________________________calculated  49.86  4.54        17.89                               22.64found       49.89  4.56        17.87                               22.42______________________________________

Examples 35 to 37 were synthesized according to the process described in Example 3, by reacting 5-hydroxy-2-nitroaniline in Stage 1 with the corresponding halogenated compound.

EXAMPLE 35 2-Hydroxymethyl-5-(4-pyridyloxy)benzimidazole dihydrochloride

Melting point: 220 C.

______________________________________Elemental microanalysis:     C %  H %         N %    Cl %______________________________________calculated  49.70  4.17        13.37                               22.57found       49.51  4.31        13.22                               22.81______________________________________
EXAMPLE 36 2-Phenoxymethyl-5-(4-pyridylmethoxy)benzimidazole

Melting point: 162 C.

______________________________________Elemental microanalysis:   C %         H %    N %______________________________________calculated     72.49         5.17   12.68found     72.34         5.32   12.69______________________________________
EXAMPLE 37 2-Hydroxymethyl-5-(4-pyridylmethoxy)benzimidazole dihydrochloride

Melting point: >260 C.

______________________________________Elemental microanalysis:     C %  H %         N %    Cl %______________________________________calculated  51.24  4.61        12.80                               21.60found       51.19  5.09        12.88                               21.49______________________________________
EXAMPLE 38 2-Phenoxymethyl-5-(4-pyridylmethyl)benzimidazole dihydrochloride

The expected compound was synthesized according to the process described in Example 3, Stages 2 and 3, using 2-nitro-4-(4-pyridylmethyl)aniline in Stage 2.

Melting point: 160 C.

______________________________________Elemental microanalysis:     C %  H %         N %    Cl %______________________________________calculated  61.87  4.93        10.82                               18.26found       62.03  5.08        10.87                               18.62______________________________________

Examples 39 and 40 were obtained by methylation of the compound of Example 3, followed by separation by chromatography on a silica column.

EXAMPLE 39 1-Methyl-2-hydroxymethyl-5-phenoxybenzimidazole hydrochloride

Melting point: 194 C.

______________________________________Elemental microanalysis:     C %  H %         N %    Cl %______________________________________calculated  61.97  5.20        9.63 12.19found       61.88  5.22        9.54 12.01______________________________________
EXAMPLE 40 3-Methyl-2-hydroxymethyl-5-phenoxybenzimidazole hydrochloride

Melting point: 164 C.

______________________________________Elemental microanalysis:     C %  H %         N %    Cl %______________________________________calculated  61.97  5.20        9.63 12.19found       62.05  5.06        9.60 12.28______________________________________

The compounds of the examples which follow were prepared from the corresponding starting materials.

EXAMPLE 41 2-Phenoxymethyl-5-(4-pyridylthiomethyl)benzimidazole EXAMPLE 42 2-Cyclohexyloxymethyl-5-(4-pyridylthio)benzimidazole EXAMPLE 43 2-(4-Chlorophenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 44 2-(3,4-Dichlorophenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 45 2-(2,4-Dichlorophenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 46 2-(4-Methoxyphenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 47 2-(4-Fluorophenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 48 2-(3,4,5-Trimethoxyphenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 49 2-(2,6-Dimethoxyphenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 50 2-[3-(Trifluoromethyl)phenoxy]methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 51 2-[3,5-Bis(trifluoromethyl)phenoxy]methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 52 2-(4-Phenylphenoxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 53 2-[4-(4-Methylphenyl)bicyclo[2.2.2]oct-1-yloxy]methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 54 2-[4-(4-Methoxybicyclo[2.2.2]oct-1-yl)phenoxy]methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 55 2-Phenylthiomethyl-5-(3-pyridylthio)benzimidazole EXAMPLE 56 2-Phenylsulfonylmethyl-5-(4-pyridylthio)benzimidazole EXAMPLE 57 2-(4-Pyridyloxy)methyl-5-(4-pyridylthio)benzimidazole EXAMPLE 58 2-Phenoxymethyl-5-(1-phenyl-1-hydroxymethyl)benzimidazole EXAMPLE 59 2-(4-Pyridyloxy)methyl-5-(1-phenyl-1-hydroxymethyl)benzimidazole EXAMPLE 60 2-Phenoxymethyl-5-[1-(3-pyridyl)-2-hydroxyethyl]benzimidazole EXAMPLE 61 2-(4-Pyridyloxy)methyl-5-[1-(3-pyridyl)-2-hydroxyethyl]benzimidazole EXAMPLE 62 2-Phenoxymethyl-5-[(3-pyridyl)methylthiomethyl]benzimidazole EXAMPLE 63 2-Phenoxymethyl-5-[2-(3-pyridyl)ethoxy]benzimidazole EXAMPLE 64 2-Phenoxymethyl-5-[4-(dimethylamino)phenoxy]benzimidazole EXAMPLE 65 2-Phenoxymethyl-5-[(3-pyridyl)thio]benzimidazole EXAMPLE 66 Pharmacological study of the compounds of the invention

The compounds were studied on the monocyte/macrophage type human cell line THP1. The production of IL-1β by these cells was obtained after stimulation with bacterial lipopolysaccharide (M. Turner et coll., Biochem. Biophys. Res. Comm., 1988, 256(2), 830-839) and assayed by the EIA method (Cayman kit) according to the instructions supplied by the manufacturer. In the test of endotoxic shock induced in mice by intravenous injection of lipopolysaccharide, the compounds of the invention decreased the circulating levels of TNFα by approximately 50% for an oral dose of 100 mg/kg.

EXAMPLE 67 Pharmaceutical Composition

Preparation formula for 1000 tablets containing a dose of 10 mg

Compound of Example 2 . . . 10 g

Hydroxypropylcellulose . . . 2 g

Wheat starch . . . 10 g

Lactose . . . 100 g

Magnesium stearate . . . 3 g

Talc . . . 3 g

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4430502 *Aug 13, 1982Feb 7, 1984The Upjohn CompanyPyridinyl substituted benzimidazoles and quinoxalines
US5141950 *Sep 14, 1990Aug 25, 1992Pfizer Inc.Benzimidazole compounds and their use
JPH02306916A * Title not available
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6127389 *Oct 21, 1999Oct 3, 2000Fujisawa Pharmaceutical Co., Ltd.Benzimidazole derivatives as bradykinin agonists
US6248770 *Jun 24, 1999Jun 19, 2001Boehringer Ingelheim Pharma KgBenzimidazoles having antithrombotic activity
US6451832Dec 12, 2000Sep 17, 2002Boehringer Ingelheim Pharma KgBenzimidazoles with antithrombotic activity
US6486204Jan 26, 2001Nov 26, 2002Merck & Co., Inc.Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug
US6593355Jul 3, 2002Jul 15, 2003Boehringer Ingelehim Pharma KgBenzimidazoles with antithrombotic activity
US6660858Mar 28, 2001Dec 9, 2003Lion Bioscience Ag2-aminobenzoxazole derivatives and combinatorial libraries thereof
US7482367Aug 30, 2006Jan 27, 2009Novartis Vaccines And Diagnostics, Inc.Substituted benzimidazoles and methods of their use
US7598393Nov 2, 2005Oct 6, 2009Pfizer Inc.Sulfonyl benzimidazole derivatives
US7732465Dec 5, 2008Jun 8, 2010Novartis Vaccines And Diagnostics, Inc.Substituted benzimidazoles and methods of their use
US7767820May 5, 2008Aug 3, 2010Novartis Vaccines And Diagnostics, Inc.Substituted benzimidazoles and methods of preparation
US8592459Apr 13, 2010Nov 26, 2013Novartis AgSubstituted benzimidazoles and methods of their use
US8653063 *Jan 22, 2010Feb 18, 2014Raqualia Pharma Inc.N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity
US8912336Nov 8, 2010Dec 16, 2014Vanderbilt UniversityAryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8946264Oct 20, 2012Feb 3, 2015Daiichi Sankyo Company, LimitedPyridine derivative
US20110281840 *Jan 22, 2010Nov 17, 2011Kazuo AndoN-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
Classifications
U.S. Classification514/338, 548/309.7, 514/394, 548/304.4, 546/256, 514/312, 548/310.4, 546/273.4, 546/153, 514/333, 548/310.1
International ClassificationC07D235/06, C07D403/12, A61K31/4184, C07D401/12, C07D401/14, A61K31/428, C07D277/64, C07D235/14, A61K31/4427, A61K31/44, C07D401/06, A61P43/00, A61K31/42, C07D235/10, A61K31/423, A61K31/425, A61K31/415, C07D263/56, C07D235/12, A61K31/47, A61P29/00
Cooperative ClassificationC07D401/14, C07D235/14, C07D235/06, C07D403/12, C07D401/06, C07D401/12, C07D235/12, C07D235/10
European ClassificationC07D235/06, C07D235/14, C07D235/12, C07D235/10, C07D401/14, C07D401/12, C07D403/12, C07D401/06
Legal Events
DateCodeEventDescription
Dec 18, 2007FPExpired due to failure to pay maintenance fee
Effective date: 20071026
Oct 26, 2007LAPSLapse for failure to pay maintenance fees
May 16, 2007REMIMaintenance fee reminder mailed
Jan 29, 2003FPAYFee payment
Year of fee payment: 4
Jan 14, 2002ASAssignment
Owner name: LES LABORATOIRES SERVIER, FRANCE
Free format text: MERGER;ASSIGNOR:ADIR ET COMPAGNIE;REEL/FRAME:012475/0568
Effective date: 20010730
Owner name: LES LABORATOIRES SERVIER 22 RUE GARNIER NEUILLY-SU
Owner name: LES LABORATOIRES SERVIER 22 RUE GARNIERNEUILLY-SUR
Free format text: MERGER;ASSIGNOR:ADIR ET COMPAGNIE /AR;REEL/FRAME:012475/0568
Owner name: LES LABORATOIRES SERVIER 22 RUE GARNIERNEUILLY-SUR
Free format text: MERGER;ASSIGNOR:ADIR ET COMPAGNIE /AR;REEL/FRAME:012475/0568
Effective date: 20010730
Owner name: LES LABORATOIRES SERVIER 22 RUE GARNIER NEUILLY-SU
Free format text: MERGER;ASSIGNOR:ADIR ET COMPAGNIE;REEL/FRAME:012475/0568
Effective date: 20010730
May 2, 2000CCCertificate of correction
Dec 19, 1997ASAssignment
Owner name: ADIR ET COMPAGNIE, FRANCE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE NANTEUIL, GUILLAUME;PORTEVIN, BERNARD;BONNET, JACQUELINE;AND OTHERS;REEL/FRAME:008872/0540
Effective date: 19970707